triazoles has been researched along with mk-1775 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dosaka-Akita, H; Furuta, M; Kikuchi, E; Kikuchi, H; Kikuchi, J; Kinoshita, I; Konno, S; Maeda, M; Sakakibara-Konishi, J; Shoji, T; Suzuki, M; Takashima, Y | 1 |
1 other study(ies) available for triazoles and mk-1775
| Article | Year |
|---|---|
Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azepines; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA End-Joining Repair; DNA-Binding Proteins; Drug Synergism; Female; Gene Knockdown Techniques; Heterocyclic Compounds, 2-Ring; Humans; Lung Neoplasms; Mice; Piperazines; Protein-Tyrosine Kinases; Pyrazoles; Pyridazines; Pyrimidinones; Transcription Factors; Triazoles; Xenograft Model Antitumor Assays | 2020 |